← All trials
NCT06329674
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 27, 2021
- Primary completion
- Dec 1, 2022
- Completion date
- Jun 13, 2023
- First posted
- Mar 26, 2024
- Last posted
- Mar 26, 2024
- Enrollment
- 235
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aju PharmLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.